Literature DB >> 34714302

Immunogenic cell death inducers for enhanced cancer immunotherapy.

Yanhua Li1, Xiaohan Liu1, Xia Zhang1, Wei Pan1, Na Li1, Bo Tang1.   

Abstract

Inducing the immunogenic cell death (ICD) of cancer cells is an important method to improve the immunogenicity of tumor cells for enhanced cancer immunotherapy. Therefore, we discuss the ICD process and then highlight various ICD inducers and strategies for triggering the ICD of cancer cells. We hope that this Feature Article will inspire readers to develop more effective ICD inducers.

Entities:  

Mesh：

Year:  2021        PMID： 34714302     DOI： 10.1039/d1cc04604g

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  5 in total

1.  Identification of the Marine Alkaloid Lepadin A as Potential Inducer of Immunogenic Cell Death.

Authors:  Genoveffa Nuzzo; Carmela Gallo; Fabio Crocetta; Lucia Romano; Giusi Barra; Giuseppina Senese; Mario dell'Isola; Dalila Carbone; Valentina Tanduo; Federica Albiani; Guido Villani; Giuliana d'Ippolito; Emiliano Manzo; Angelo Fontana
Journal:  Biomolecules       Date:  2022-02-02

Review 2.  When Onco-Immunotherapy Meets Cold Atmospheric Plasma: Implications on CAR-T Therapies.

Authors:  Xiaofeng Dai; Jitian Li; Yiming Chen; Kostya Ken Ostrikov
Journal:  Front Oncol       Date:  2022-02-23       Impact factor: 6.244

3.  A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody.

Authors:  Zhilin Li; Hao Cai; Zhiqian Li; Long Ren; Xuelei Ma; Hongyan Zhu; Qiyong Gong; Hu Zhang; Zhongwei Gu; Kui Luo
Journal:  Bioact Mater       Date:  2022-09-13

4.  Comprehensive characterisation of immunogenic cell death in melanoma revealing the association with prognosis and tumor immune microenvironment.

Authors:  Jie Ren; Jiaqi Yang; Song Na; Yiqian Wang; Linyun Zhang; Jinkui Wang; Jiwei Liu
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

5.  Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses.

Authors:  Jeongrae Kim; Yongwhan Choi; Suah Yang; Jaewan Lee; Jiwoong Choi; Yujeong Moon; Jinseong Kim; Nayeon Shim; Hanhee Cho; Man Kyu Shim; Sangmin Jeon; Dong-Kwon Lim; Hong Yeol Yoon; Kwangmeyung Kim
Journal:  Pharmaceutics       Date:  2022-02-22       Impact factor: 6.321
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.